Cytotoxicity of Cytokine-Induced Killer Cells Coated with Bispecific Antibody Against Acute Myeloid Leukemia Cells

References

• Yeager A. M., Kaizer H., Santos G. W., Saral R., Colvin O. M., Stuart R. K., Braine H. G., Burke P. J., Ambinder R. F., Burns W. H., Fuller D. J., Davis J. M., Karp J. E., May W. S., Rowley S. D., Sesenbrenner L. L., Vogelsang G. B., Wingard J. R. Autologous bone marrow transplantation with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperox-ycyclophosphamide. N. Engl. J. Med. 1986; 315: 141–147
   PubMed Web of Science ®Google Scholar
• Gale R. P., Horowitz M. M., Butturini A. Autotransplants in acute leukaemia. Br. J. Haematol. 1991; 78: 135–137
   PubMed Web of Science ®Google Scholar
• Bortin M. M., Horowitz M. M., Rowlings P. A., Rimm A. A., Sobocinski K. A., Zhang M. J., Gale R. P., For the Advisory Committee of the International Bone Marrow Transplant Registry. 1993 Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1993; 12: 97–104
   PubMed Web of Science ®Google Scholar
• Higuchi C. M., Thompson J. A., Petersen F. B., Buckner C. D., Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561–2568
   PubMed Web of Science ®Google Scholar
• Fefer A., Benyunes M., Higuchi C., York A., Massumoto C., Lindgren C., Buckner C. D., Thompson J. A. Interleukin-2+lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Haematol. 1993; 89: 2–7
   PubMed Web of Science ®Google Scholar
• Weisdorf D. J., Anderson P. M., Blazar B. R., Uckun F. M., Kersey J. H., Ramsay N. K. Transplantation 1993; 55: 61–66
   PubMed Web of Science ®Google Scholar
• Klingemann H. G. Trying to overcome residual disease after bone marrow transplantation for hematologic malignancies. Leukemia & Lymphoma 1992; 8: 421–429
   PubMed Web of Science ®Google Scholar
• Faber L. M., van Luxemburg-Heijs S. A. P., Willemze R., Falkenbug J. H. F. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J. Exp. Med. 1992; 176: 1283–1289
   PubMed Web of Science ®Google Scholar
• Oshimi K., Oshimi Y., Motoji T., Kobayashi S., Mizoguchi H. Lysis of leukemia and lymphoma cells by autologous and allogeneic interferon-activated blood mononuclear cells. Blood 1985; 61: 790–798
   Web of Science ®Google Scholar
• Oshimi K., Oshimi Y., Akutsu M., Takei Y., Saito H., Okada M., Mizoguchi H. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 68: 938–948
   PubMed Web of Science ®Google Scholar
• Lotzova E., Savary C. A., Herberman R. B. Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J. Immunol. 1987; 138: 2718–2727
   PubMed Web of Science ®Google Scholar
• Fierro M. T., Liao X.-S., Lusso P., Bonferroni M., Ma-Tera L., Cesano A., Lista P., Arione R., Forni G., Foa R. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 1988; 2: 50–54
   PubMed Web of Science ®Google Scholar
• Alder A., Chervenick P. A., Whiteside T. L., Lotzova E., Herberman R. B. Interleukin 2 induction of lymphokine-activated killer (LAIC) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 1988; 71: 709–716
   PubMed Web of Science ®Google Scholar
• Tahara T., Iseki R., Morishima Y., Yokomaku S., Ohno R., Saito H. Generation and characterization of lymphokine-activated killer cells against fresh human leukemia cells. Jpn. J. Cancer Res. 1988; 79: 390–399
   PubMedGoogle Scholar
• Archimbaud E., Bailly M., Dore J.-F. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. Br. J. Haematol. 1991; 77: 328–334
   PubMed Web of Science ®Google Scholar
• Oshimi K., Oshimi Y., Satake M., Mizoguchi H. Natural-killer mediated lysis of normal and malignant target cells, and its regulation by monocytes. J. Exp. Med. 1985; 162: 472–486
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Mule J. J. New approaches to the immunotherapy of cancer using interleukin-2. Ann. Int. Med. 1988; 108: 853–864
   PubMed Web of Science ®Google Scholar
• Benyunes M. C., Massumoto C., York A., Higuchi C. M., Buckner C. D., Thompson J. A., Petersen F. B., Fefer A. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12: 159–163
   PubMed Web of Science ®Google Scholar
• Gaynor E. R., Vitek L., Sticklin L., Creekmore S. P., Ferraro M. E., Thomas J. X., Fisher S. G., Fisher R. I. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Int. Med. 1988; 109: 953–958
   PubMed Web of Science ®Google Scholar
• Isner J. M., Dietz W. A. Cardiovascular consequences of recombinant DNA technology: Interleukin-2. Ann. Int. Med. 1988; 109: 933–935
   PubMed Web of Science ®Google Scholar
• Lee R. E., Lotze M. T., Skibber J. M., Tucher E., Bonow R. O., Ognibene F. P., Carrasquillo J. A., Shelhamer J. H., Parrillo J. E., Rosenberg S. A. Cardiorespiratory effects of immunotherapy with interleukin-2. J. Clin. Oncol. 1989; 7: 7–20
   PubMed Web of Science ®Google Scholar
• Ettinghausen S. E., Moore J. G., White D. E., Platanias L., Young N. S., Rosenberg S. A. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 1987; 69: 1654–1660
   PubMed Web of Science ®Google Scholar
• Lotzova E. Role of interleukin-2 activated MHC-non-restricted lymphocytes in antileukemia activity and therapy. Leukemia & Lymphoma 1992; 7: 15–28
   PubMed Web of Science ®Google Scholar
• Jung G., Eberhard H. J. M. An in vitro model for tumor immunotherapy with antibody heteroconjugates. Immunol. Today 1988; 9: 257–260
   PubMedGoogle Scholar
• Songsivilai S., Lachmann P. J. Bispecific antibody: a tool for diagnosis and treatment of disease. Clin. Exp. Immunol. 1990; 79: 315–321
   PubMed Web of Science ®Google Scholar
• Bolhuis R. L. H., Sturm E., Braakman E. T cell targeting in cancer therapy. Cancer Immunol. Immunother. 1991; 34: 1–8
   PubMed Web of Science ®Google Scholar
• Nitta T., Sato K., Yagita H., Okumura K. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990; 335: 368–371
   PubMed Web of Science ®Google Scholar
• Oshimi K., Seto T., Oshimi Y., Masuda M., Okumura K., Mizoguchi H. Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD 10 Fab' antibody. Blood 1991; 77: 1044–1049
   PubMed Web of Science ®Google Scholar
• Kaneko T., Fusauchi Y., Kakui Y., Masuda M., Akahoshi M., Teramura M., Motoji T., Okumura K., Mizoguchi H., Oshimi K. A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells. Blood 1993; 81: 1333–1341
   PubMed Web of Science ®Google Scholar
• Haagen I. A., van de Griend R., Clark M., Geerars A., Bast B., de Gast B. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (αCD3/αCD19). Clin. Exp. Immunol. 1992; 90: 368–375
   PubMed Web of Science ®Google Scholar
• Anderson P. M., Crist W., Hasz D., Carroll A. J., Myers D. E., Uckun F. M. G 19.4 (aCD3) x B43 (aCD19) monoclonal antibody heteroconjugate triggers CD 19 antigen-specific lysis of t(4:11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 1992; 80: 2826–2934
   PubMed Web of Science ®Google Scholar
• Nitta T., Yagita H., Azuma T., Sato K., Okumura K. Bispecific F(ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells. Eur. J. Immunol. 1989; 19: 1437–1441
   PubMed Web of Science ®Google Scholar
• Nitta T., Sato K., Okumura K., Ishii S. Induction of cytotoxicity in human T cells coated with anti-glioma X anti-CD3 bispecific antibody against human glioma cells. J. Neurosurg. 1990; 72: 476–481
   PubMed Web of Science ®Google Scholar
• Burke F., Naylor M. S., Davies B., Balkwill F. Cytokine wall chart. Immunol. Today 1993; 14: 167–170
   Google Scholar
• Aggarwal B. B., Gutterman J. U. Human Cytokines. Handbook for basic and clinical research. Blachwell Scientific Publications. 1992
   Google Scholar
• Ochoa A. C., Gromo G., Alter B. J., Sondel P. M., Bach F. H. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, β-IL 1, interferon-γ and β1. J. Immunol. 1987; 138: 2728–2733
   PubMed Web of Science ®Google Scholar
• Anderson P. M., Ochoa A. C., Ramsay N. K. C., Hasz D., Weisdorf D. Anti-CD3 + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity. Blood 1992; 80: 1846–1853
   PubMed Web of Science ®Google Scholar
• Kaufmann Y., Davidson J., Levanon M., Icekson I., Revel M., Ramot B. Lymphokine-activated killer (LAK) cells: Interferon-g synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations. Clin. Immunol. Immunopath. 1991; 58: 278–288
   PubMedGoogle Scholar
• Schmidt-Wolf I. G. H., Negrin R. S., Kiem H.-P., Blume K. G., Weissman I. L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 1991; 174: 139–149
   PubMed Web of Science ®Google Scholar
• Teichmann J. V., Ludwig W.-D., Thiel E. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. Leuk. Res. 1992; 16: 287–298
   PubMed Web of Science ®Google Scholar
• Stotter H., Custer M. C., Bolton E. S., Guedez L., Lotze M. T. IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4. J. Immunol. 1991; 146: 150–155
   PubMed Web of Science ®Google Scholar
• Hickman C. J., Crim J. A., Mostowski H. S., Siegel J. P. Regulation of human cytotoxic T lymphocyte development by IL-7. J. Immunol. 1990; 145: 2415–2420
   PubMed Web of Science ®Google Scholar
• Alderson M. R., Sassenfeld H. M., Widmer M. B. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J. Exp. Med. 1990; 172: 577–587
   PubMed Web of Science ®Google Scholar
• Smyth M. J., Norihisa Y., Gerard J. R., Young H. A., Ortardo J. R. IL-7 regulation of cytotoxic lymphocytes: pore-forming protein gene expression, interferon-γ production, and cytotoxicity of human peripheral blood lymphocyte subsets. Cell. Immunol. 1991; 138: 390–403
   PubMed Web of Science ®Google Scholar
• Welch P. A., Namen A. E., Goodwin R. G., Armitage R., Cooper M. D. Human IL-7: A novel T cell growth factor. J. Immunol. 1989; 143: 3562–3567
   PubMed Web of Science ®Google Scholar
• Teichmann J. V., Ludwig W.-D., Thiel E. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: Analysis of 252 samples. Nat. Immun. 1992; 11: 117–132
   PubMedGoogle Scholar
• Teichmann J. V., Ludwig W.-D., Thiel E. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells. Int. J. Haematol. 1992; 55: 255–264
   PubMed Web of Science ®Google Scholar
• Cesano A., Lista P., Bellone G., Geuna M., Brizzi M. F., Rossi P. R., Pegoraro L., Oberholtzer E., Matera L. Effect of human interleukin-3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity. Leukemia 1992; 6: 567–573
   PubMed Web of Science ®Google Scholar
• Palucka A. K., Porwit A., Reizenstein P. Resistance of leukemia blasts to lymphokine activated killer (LAK)-mediated cytotoxicity is not related to their adhesion properties. Eur. J. Haematol. 1991; 47: 123–127
   PubMed Web of Science ®Google Scholar
• Palucka A. K., Porwit A., Reizenstein P. A supportive role of neural cell adhesion molecule (NCAM) in adhesion between leukaemic blasts and cytotoxic lymphocytes. Scand. J. Immunol. 1992; 35: 399–406
   PubMed Web of Science ®Google Scholar
• Archimbaud E., Thomas X., Campos L., Fiere D., Dore J.-F. Susceptibility of acute myelogeneous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance. Leuk. Res. 1992; 16: 673–680
   PubMed Web of Science ®Google Scholar
• Oblakowski P., Bello-Femandez C., Reittie J. E., Heslop H. E., Galatowicz G., Veys P., Wilkes S., Prentice H. G., Hazlehurst G., Hoffbrand A. V., Brenner M. K. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. Blood 1991; 77: 1996–2001
   PubMed Web of Science ®Google Scholar
• Allavene P., Grandi M., D'Incalci M., Geri O., Giuliani F. C., Mantovani. A. Int. J. Cancer, 40: 104–107
   PubMed Web of Science ®Google Scholar
• Harker W. G., Tom C., McGregor J. R., Slade L., Samlowski W. E. Human tumor cell line resistance to chemotherapeutic agent does not predict resistance to natural killer of lymphokine-activated killer cell-mediated cytolysis. Cancer Res. 1990; 50: 5931–5936
   PubMed Web of Science ®Google Scholar
• Gerlach J. H., Kartner N., Bell D. R., Ling V. Multidrug resistance. Cancer Sur. 1986; 5: 25–46
   PubMedGoogle Scholar
• Treichel R. S., Olken S. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines. Int. J. Cancer 1992; 50: 305–310
   PubMed Web of Science ®Google Scholar
• Dupuis M. L., Romani C., Yassen A., Samogia P., Tombesi M., Caserta M., Cianfriglia M. The over expression of P-glycoprotein in K-562 and DAUDI cells, is associated with a high susceptibility to NK and LAK cells. J. Biol. Regul. Homeost. Agents 1991; 5: 137–141
   PubMed Web of Science ®Google Scholar
• Dupuis M. L., Ramoni C., Yassen A., Samoggia P., Tombesi M., Caserta M., Cianfriglia M. The over-expression of P-glycoprotein in K-562 and Daudi cells, is associated with a high susceptibility to NK and LAK cells. J. Biol. Regul. Homeost. Agents 1991; 5: 137–141
   PubMed Web of Science ®Google Scholar
• Arienti F., Gambacorti-Passerini C., Borin L., Rivoltini L., Orazi A., Pogliani E. M., Corneo G., Parmiani G. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemia cells without changes in drug resistance or in the expression of adhesion molecules. Ann. Oncol. 1992; 3: 155–162
   PubMed Web of Science ®Google Scholar
• Filgueira L., Zuber M., Juretic A., Luscher U., Caetano V., Harder F., Garotta G., Heberer M., Spagnoli G. C. Differential effects of interleukin-2 and CD3 triggering on cytokine gene transcription and secretion in cultured tumor infiltrating lymphocytes. Cell. Immunol. 1993; 150: 205–218
   PubMed Web of Science ®Google Scholar
• Oshimi K., Oshimi Y., Saito H., Mizoguchi H. Cytotoxicity of interleukin-2-activated lymphocytes for autologous normal blood mononuclear cells. J. Immunol. Methods 1988; 109: 161–168
   PubMed Web of Science ®Google Scholar
• Robertson M. J., Manley T. J., Donahue C., Levine H., Ritz J. Costimulatory signals are required for optimal proliferation of human natural killer cells. J. Immunol. 1993; 150: 1705–1714
   PubMed Web of Science ®Google Scholar